Sarepta Therapeutics (SRPT) Stock Price, Quote & News

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dyst...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 274 4000

Website: www.sarepta.com

Address:

215 First Street, Suite 415, Cambridge, United States

4Reel Jun. 4 at 2:29 PM

$SRPT still lagging xbi again. It should be exponential 2-4x. Like when it was down 4% this week srpt was down 8%. Cmon

0 · Reply

biomaster22 Jun. 4 at 2:20 PM

$SRPT what a joke all of these scumbags just stealing shareholders money ! Only people earning their salary are the scientist’s trying to help these kids

0 · Reply

Initiator1 Jun. 4 at 2:15 PM

$SRPT Very hostile questions by the shareholders

1 · Reply

fpak Jun. 4 at 2:01 PM

$SRPT Time to announce the buyout.

1 · Reply

Loore Jun. 4 at 1:53 PM

$SRPT Rally cap.

0 · Reply

fpak Jun. 4 at 1:46 PM

$SRPT $16.50 and then handbreak. Who would have guessed....

0 · Reply

Find_the_Cure Jun. 4 at 1:42 PM

$SRPT looks like max pain is again $18 for weekly options expiration tomorrow.

0 · Reply

1K21Mil Jun. 4 at 1:36 PM

$SRPT Seems like it wants to go back to $18 by tomorrow. Good luck!

1 · Reply

fpak Jun. 4 at 1:30 PM

$SRPT Im scared. Everytime they talk this goes down the toilet.

1 · Reply

Initiator1 Jun. 4 at 12:06 PM

$SRPT What’s to be expected from AGM?

1 · Reply

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

2026-05-15T12:30:23.000Z - 20 days ago

Sarepta price target lowered to $19 from $20 at Evercore ISI

May 13, 2026, 4:30 PM EDT - 21 days ago

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

2026-05-07T00:41:58.000Z - 4 weeks ago

Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Sarepta Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Sarepta Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Sarepta Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Sarepta Therapeutics Slides: Q1 2026

May 6, 2026, 4:05 PM EDT - 4 weeks ago

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

Sarepta Therapeutics Proxy statement: Proxy filing

Apr 22, 2026, 8:30 AM EDT - 6 weeks ago

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

2026-04-16T16:20:19.000Z - 6 weeks ago

Roche decision could hurt Sarepta in U.S., says H.C. Wainwright

2026-04-07T15:08:48.000Z - 2 months ago

Sarepta price target raised to $19 from $18 at RBC Capital

Mar 31, 2026, 4:05 PM EDT - 2 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-03-26T12:40:44.000Z - 2 months ago

Deutsche ups Sarepta target, says 35% stock rally overdone

2026-03-26T12:37:02.000Z - 2 months ago

Sarepta price target raised to $35 from $29 at Wedbush

2026-03-26T09:56:24.000Z - 2 months ago

Sarepta price target raised to $13 from $9 at Citi

2026-03-25T19:50:31.000Z - 2 months ago

Sarepta price target raised to $25 from $20 at Morgan Stanley

2026-03-25T14:10:14.000Z - 2 months ago

Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink

2026-03-25T13:55:34.000Z - 2 months ago

Sarepta early DM1 data ‘appear promising,’ says Oppenheimer

Mar 25, 2026, 8:30 AM EDT - 2 months ago

Sarepta Therapeutics Transcript: Study result

Mar 25, 2026, 8:30 AM EDT - 2 months ago

Sarepta Therapeutics Press release: Study result

Mar 25, 2026, 8:30 AM EDT - 2 months ago

Sarepta Therapeutics Slides: Study result

2026-03-25T12:10:47.000Z - 2 months ago

Sarepta announces first clinical data from pipeline targeting FSHD1, DM1

Mar 25, 2026, 8:05 AM EDT - 2 months ago

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Mar 24, 2026, 4:05 PM EDT - 2 months ago

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Mar 19, 2026, 8:30 AM EDT - 2 months ago

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

Mar 16, 2026, 8:33 AM EDT - 2 months ago

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Mar 3, 2026, 1:50 PM EST - 3 months ago

Sarepta Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 27, 2026, 9:00 AM EST - 3 months ago

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

Feb 26, 2026, 8:30 AM EST - 3 months ago

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

Feb 26, 2026, 5:05 AM EST - 3 months ago

Sarepta Therapeutics CEO Ingram to retire by year end

Feb 25, 2026, 4:30 PM EST - 3 months ago

Sarepta Therapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Sarepta Therapeutics Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Sarepta Therapeutics Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 3 months ago

Sarepta Therapeutics Slides: Q4 2025

Feb 25, 2026, 4:05 PM EST - 3 months ago

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

Feb 24, 2026, 9:07 AM EST - 3 months ago

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

Feb 24, 2026, 8:30 AM EST - 3 months ago

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 11, 2026, 8:30 AM EST - 4 months ago

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Feb 4, 2026, 8:30 AM EST - 4 months ago

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

Jan 26, 2026, 8:53 AM EST - 4 months ago

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys

Jan 26, 2026, 8:30 AM EST - 4 months ago

Sarepta Therapeutics Transcript: Study result

Jan 26, 2026, 8:30 AM EST - 4 months ago

Sarepta Therapeutics Press release: Study result

Jan 26, 2026, 8:30 AM EST - 4 months ago

Sarepta Therapeutics Slides: Study result

Jan 26, 2026, 8:10 AM EST - 4 months ago

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

Jan 26, 2026, 8:00 AM EST - 4 months ago

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Jan 23, 2026, 4:05 PM EST - 4 months ago

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Jan 12, 2026, 12:00 PM EST - 5 months ago

Sarepta Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:00 PM EST - 5 months ago

Sarepta Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:58 AM EST - 5 months ago

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Jan 12, 2026, 9:30 AM EST - 5 months ago

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Jan 7, 2026, 8:30 AM EST - 5 months ago

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Jan 5, 2026, 8:30 AM EST - 5 months ago

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 7:00 AM EST - 6 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Nov 25, 2025, 8:57 AM EST - 6 months ago

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Nov 24, 2025, 7:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

ARWR

Nov 24, 2025, 7:30 AM EST - 6 months ago

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Nov 14, 2025, 2:54 PM EST - 7 months ago

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Nov 14, 2025, 2:08 PM EST - 7 months ago

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Nov 4, 2025, 9:55 AM EST - 7 months ago

Sarepta Therapeutics shares plunge after disappointing trial data

Nov 4, 2025, 6:20 AM EST - 7 months ago

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Nov 4, 2025, 4:27 AM EST - 7 months ago

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Nov 3, 2025, 6:26 PM EST - 7 months ago

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Nov 3, 2025, 4:30 PM EST - 7 months ago

Sarepta Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 7 months ago

Sarepta Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 7 months ago

Sarepta Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 7 months ago

Sarepta Therapeutics Slides: Q3 2025

Nov 3, 2025, 4:24 PM EST - 7 months ago

Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:05 PM EST - 7 months ago

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Oct 27, 2025, 4:05 PM EDT - 7 months ago

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Oct 23, 2025, 6:46 AM EDT - 8 months ago

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

BLSH DASH FLY IREN NEM OPEN QS

Oct 3, 2025, 8:30 AM EDT - 8 months ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Sep 5, 2025, 9:00 AM EDT - 9 months ago

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

Aug 25, 2025, 3:11 AM EDT - 10 months ago

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

Aug 23, 2025, 7:08 AM EDT - 10 months ago

SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)

Aug 21, 2025, 7:00 AM EDT - 10 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

4Reel Jun. 4 at 2:29 PM

$SRPT still lagging xbi again. It should be exponential 2-4x. Like when it was down 4% this week srpt was down 8%. Cmon

0 · Reply

biomaster22 Jun. 4 at 2:20 PM

$SRPT what a joke all of these scumbags just stealing shareholders money ! Only people earning their salary are the scientist’s trying to help these kids

0 · Reply

Initiator1 Jun. 4 at 2:15 PM

$SRPT Very hostile questions by the shareholders

1 · Reply

fpak Jun. 4 at 2:01 PM

$SRPT Time to announce the buyout.

1 · Reply

Loore Jun. 4 at 1:53 PM

$SRPT Rally cap.

0 · Reply

fpak Jun. 4 at 1:46 PM

$SRPT $16.50 and then handbreak. Who would have guessed....

0 · Reply

Find_the_Cure Jun. 4 at 1:42 PM

$SRPT looks like max pain is again $18 for weekly options expiration tomorrow.

0 · Reply

1K21Mil Jun. 4 at 1:36 PM

$SRPT Seems like it wants to go back to $18 by tomorrow. Good luck!

1 · Reply

fpak Jun. 4 at 1:30 PM

$SRPT Im scared. Everytime they talk this goes down the toilet.

1 · Reply

Initiator1 Jun. 4 at 12:06 PM

$SRPT What’s to be expected from AGM?

1 · Reply

murphylaw Jun. 4 at 11:35 AM

$SRPT Roche buyout for $50 just around the corner. Perfect setup.

2 · Reply

maxmemax Jun. 4 at 11:09 AM

$SRPT Let me guess, you ran to Thailand so that SEC cannot get to you for your fake insider information bs

0 · Reply

HannahC Jun. 4 at 11:06 AM

$SRPT If you want exposure to the future of genetic medicine in rare diseases, $SRPT is still one of the best shots out there. Period.

0 · Reply

Gianluca_Ford Jun. 4 at 10:57 AM

$SRPT isn’t some speculative dream anymore. They have the only approved gene therapy actually treating DMD patients today. That changes everything.

0 · Reply

TheDragonsClaw Jun. 4 at 10:53 AM

$TQQQ $DIS $SRPT $RDW ++

0 · Reply

68Horsemen Jun. 4 at 10:30 AM

$SRPT https://www.cnbc.com/2026/06/04/biotech-ma-dealmaking-pharma-106-billion.html Hopefully SRPT gets some of this love.

1 · Reply

fpak Jun. 4 at 9:06 AM

$SRPT All time low at the Annual General meeting.... Glad i dont have to open the event.

2 · Reply

Morslan Jun. 4 at 12:27 AM

$SRPT 12-22, 16-22, 16-24, 16-23 16- ? I will take 22

3 · Reply

drbrain00 Jun. 3 at 11:16 PM

$SRPT Annual general meeting tomorrow. It will be interesting how many votes went against. Even though the Board recommended directors will win, enough against votes would encourage takeover speculation.

0 · Reply

Fred_Sigma_Invest Jun. 3 at 9:02 PM

$SRPT Clowns like @Thaigrlsrk who have been pumping this since 2024 look more foolish than ever. Management has destroyed sentiment and investor confidence. The company itself has lost faith in it‘s own stock. Doug is a dope and Ian is a DEI hire but both are absolute ass clowns.

0 · Reply

murphylaw Jun. 3 at 8:36 PM

$SRPT Weren't they suppose to dose a patient with SRP-1005 in May/June? That couod be our catalyst to get thid back to 20s. $50 hopefully as soon as they announce some good news with non-amb population.

3 · Reply

Dontlookkid Jun. 3 at 8:24 PM

$SRPT mid 15$ range and rip or just rip from here would be great definitely getting to the point where chart can’t lie

0 · Reply

Market Cap	1.72B
Revenue (ttm)	2.20B
Net Income (ttm)	-713.41M
EPS (ttm)	N/A
PE Ratio	27.52
Forward PE	4.77
Profit Margin	-32.45%
Debt to Equity Ratio	0.56

Volume	3,540,300
Avg Vol	3,190,580
Day's Range	N/A - N/A
Shares Out	105.58M
Stochastic %K	92%
Beta	0.21
Analysts	Sell
Price Target	$21.78